Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Inventory Average (2019 - 2025)

Historic Inventory Average for Coherus Oncology (CHRS) over the last 7 years, with Q3 2025 value amounting to $3.3 million.

  • Coherus Oncology's Inventory Average fell 9402.47% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year decrease of 9402.47%. This contributed to the annual value of $33.4 million for FY2024, which is 3410.79% down from last year.
  • According to the latest figures from Q3 2025, Coherus Oncology's Inventory Average is $3.3 million, which was down 9402.47% from $4.0 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Inventory Average high stood at $65.4 million for Q3 2023, and its period low was $3.3 million during Q3 2025.
  • Moreover, its 5-year median value for Inventory Average was $38.6 million (2021), whereas its average is $39.6 million.
  • Its Inventory Average has fluctuated over the past 5 years, first soared by 26522.5% in 2021, then plummeted by 9402.47% in 2025.
  • Quarter analysis of 5 years shows Coherus Oncology's Inventory Average stood at $37.6 million in 2021, then decreased by 11.59% to $33.3 million in 2022, then soared by 94.54% to $64.7 million in 2023, then crashed by 59.93% to $25.9 million in 2024, then tumbled by 87.35% to $3.3 million in 2025.
  • Its Inventory Average was $3.3 million in Q3 2025, compared to $4.0 million in Q2 2025 and $3.9 million in Q1 2025.